News

Deal Announcements

Slate Pharma Receives $5 Million New Venture Capital

Monday, July 28, 2008 6:05:00 AM PDT | VentureDeal Staff
Durham, North Carolina --  Slate Pharmaceuticals has raised $5 million from a syndicate of venture capital and private equity firms, according to a report in PE Hub.

Slate Pharmaceuticals markets an FDA approved subcutaneous implantable testosterone pellet used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.

T+T holdings led the financing round, which included other undisclosed investors.  Proceed services from the funding were not disclosed.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1